Lightnews — Scholar-powered news

josh hardman @josh-hardman.bsky.social · 1d

Q3 2025 Psychedelic Investor Survey Results

Today, we share topline results from the latest in our series of psychedelics investor surveys.

Explore: psychedelicalpha.com/news/psyched...

josh hardman @josh-hardman.bsky.social · 2d

The Psychedelic News Feed: Sept 29 - Oct 5, 2025

psychedelicalpha.com/news/the-psy...

The Psychedelic News Feed: Sept 29 - Oct 5, 2025 - Psychedelic Alpha

Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing September 29, 2025.

psychedelicalpha.com

1 1

josh hardman @josh-hardman.bsky.social · 16d

Breakthrough Data, Black Box Sessions: A Closer Look at MindMed’s Phase 2b LSD for GAD Study

We speak to researchers and take a deeper dive into the published study, with a focus on dose-response, safety, and MindMed's eschewing of psychotherapy.

psychedelicalpha.com/news/breakth...

Breakthrough Data, Black Box Sessions: A Closer Look at MindMed’s Phase 2b LSD for GAD Study - Psychedelic Alpha

MindMed’s Phase 2b LSD (MM120) for generalised anxiety disorder (GAD) study, published in JAMA earlier this month, shows promising efficacy and a favourable safety profile. Here…

psychedelicalpha.com

4

josh hardman @josh-hardman.bsky.social · 19d

UK Royal College of Psychiatrists Weighs In: Promise in Psychedelics, But Hype Mustn’t Outpace Evidence

This morning, the UK's professional body for psychiatrists published a Position Statement and Guidance Booklet on the use of psychedelics.

psychedelicalpha.com/news/uk-roya...

UK Royal College of Psychiatrists Weighs In: Promise in Psychedelics, But Hype Mustn’t Outpace Evidence - Psychedelic Alpha

This morning, the UK’s Royal College of Psychiatrists published a Position Statement on psychedelics and related substances for medical use. Here, we briefly unpack the statement, as well as related…

psychedelicalpha.com

1 2 5

josh hardman @josh-hardman.bsky.social · 22d

🎯 Our signature Bullseye chart has just been refreshed, mapping the global pipeline of psychedelic drug candidates, from discovery through to (potential) approval.

Explore the latest Bullseye Charts + the full live Tracker now: psychedelicalpha.com/news/q325-ps...

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts - Psychedelic Alpha

We present the psychedelic drug development pipeline in two ‘bullseye chart’ formats, as of Q3’2025.

psychedelicalpha.com

1 2 4

josh hardman @josh-hardman.bsky.social · 27d

From the EMA to Gustave Roussy, Dr. Florence Butlen-Ducuing has witnessed Europe’s psychedelic renaissance first-hand.

I sat down with her to discuss.

psychedelicalpha.com/news/no-prej...

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance - Psychedelic Alpha

From a long stint at the European Medicines Agency’s (EMA) Office of Therapies for Neurological and Psychiatric Disorders to her present-day practice as a clinical psychiatrist at leading cancer…

psychedelicalpha.com

2

josh hardman @josh-hardman.bsky.social · Sep 8

On Thursday, we broke the news that FDA had published the Complete Response Letter (CRL) it sent to Lykos Therapeutics 13 months ago today, when it rejected its MDMA for PTSD new drug application.

Today, we take a much closer (~5,000 word) look...

More: psychedelicalpha.com/news/unpacki...

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos - Psychedelic Alpha

Last Thursday, FDA published the complete response letter (CRL) it sent to Lykos Therapeutics last year, when it rejected its MDMA for PTSD new drug application. Here, we take a closer look at the…

psychedelicalpha.com

1 3

josh hardman @josh-hardman.bsky.social · Sep 4

BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)

psychedelicalpha.com/news/breakin...

BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL) - Psychedelic Alpha

FDA has published its complete response letter (CRL) to Lykos Therapeutics, citing durability, safety, and bias concerns in rejecting MDMA therapy for PTSD. Here, we very briefly unpack the letter.

psychedelicalpha.com

2 9

josh hardman @josh-hardman.bsky.social · Sep 2

Wow, that’s amazing! Send me an email/DM to sort a coupon out 🏷️

1

josh hardman @josh-hardman.bsky.social · Aug 28

Pα+ Psychedelic Bulletin #207

- Lykos Rebrands to Resilient

- Pharma Pushes Back on Norway’s Ketamine Reimbursement Decision

- AbbVie-Gilgamesh Deal Viewed as Validation

- Psilocybin Rescheduling Petition Heads to HHS

- Much, much more...

psychedelicalpha.com/news/p%ce%b1...

Pα+ Psychedelic Bulletin #207: Lykos Rebrands to Resilient; Pharma Pushes Back on Norway’s Ketamine Reimbursement Decision; AbbVie-Gilgamesh Deal Viewed as Validation - Psychedelic Alpha

Lykos Therapeutics Rebrands to Resilient Pharmaceuticals • Pharma Pushes Back on Norway’s Off-Label Ketamine Decision • AbbVie–Gilgamesh Deal Viewed as Validation for Short-Acting Psychedelics •

psychedelicalpha.com

3 4

josh hardman @josh-hardman.bsky.social · Aug 25

Another scoop today.

One of the world's best healthcare systems has decided to reimburse generic ketamine for treatment-resistant depression.

Note that J&J's Spravato (esketamine nasal spray) is not reimbursed for TRD in the Nordic country.

Big news...

psychedelicalpha.com/news/norway-...

Norway Approves Public Funding for Generic Ketamine in Treatment-Resistant Depression - Psychedelic Alpha

This morning, in a world-first move, Norwegian regulators approved national reimbursement for the off-label use of generic ketamine in treatment-resistant depression. Here, we break the news…

psychedelicalpha.com

1 3

josh hardman @josh-hardman.bsky.social · Aug 23

July 2025 Psychedelic Patent Update

Explore our interactive database of psychedelic patent activity in July 2025 via our Pα+ interface. Plus, we look at how a new patent family provides a look at Rivo Bio.

psychedelicalpha.com/news/july-20...

July 2025 Psychedelic Patent Update - Psychedelic Alpha

Explore our interactive database of psychedelic patent activity in July 2025 via our Pα+ interface. Plus, we look at how a new patent family provides a look at Rivo Bio.

psychedelicalpha.com

1

josh hardman @josh-hardman.bsky.social · Aug 20

Discover Psychedelic Alpha like never before by using our new AI search tool, trained exclusively on in-house content and data.

Use any search bar on our website to get started, or visit our dedicated webpage: psychedelicalpha.com/ai

1 2 3

josh hardman @josh-hardman.bsky.social · Aug 18

BREAKING: Reunion Neuroscience Posts Strong Phase 2 Results for RE104 in Postpartum Depression

Read our Deep Dive coverage, including a discussion with company management, now.

psychedelicalpha.com/news/reunion...

Reunion Neuroscience Posts Strong Phase 2 Results for RE104 in Postpartum Depression - Psychedelic Alpha

This morning, Reunion Neuroscience posted positive topline results from its Phase 2 study of RE104, its 4-OH-DiPT prodrug, in postpartum depression (PPD). We spoke with Reunion leadership to dig deepe...

psychedelicalpha.com

1 4

Reposted by josh hardman

Scott Thompson, PhD @sthom003.bsky.social · Aug 12

Fantastic discussion between two excellent psychedelic scientists, spanning the generations of research progress! It really should say Huxley to Hefter to Jaster! Well done @jasteralaina.bsky.social!

josh hardman @josh-hardman.bsky.social · Aug 12

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research

psychedelicalpha.com/news/from-hu...

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research - Psychedelic Alpha

Dr. Alaina Jaster speaks with Dr. Mark Geyer in a discussion that traces his path to psychedelics research, the field’s scientific and cultural shifts, and the role of the Heffter Research Institute.

psychedelicalpha.com

2 2 6

Reposted by josh hardman

Alaina Jaster, PhD @jasteralaina.bsky.social · Aug 12

I got to interview one of my academic heroes 😎🧠🍄

Read the interesting conversation on Psychedelic Alpha!

josh hardman @josh-hardman.bsky.social · Aug 12

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research

psychedelicalpha.com/news/from-hu...

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research - Psychedelic Alpha

Dr. Alaina Jaster speaks with Dr. Mark Geyer in a discussion that traces his path to psychedelics research, the field’s scientific and cultural shifts, and the role of the Heffter Research Institute.

psychedelicalpha.com

2 4 10

josh hardman @josh-hardman.bsky.social · Aug 12

Heffter Research Institute co-founder Dr. Mark Geyer spoke with Dr. Alaina Jaster for our latest interview.

Among the topics they discussed were so-called non-hallucinogenic psychedelics.

Read more: psychedelicalpha.com/news/from-hu...

1 4 8

josh hardman @josh-hardman.bsky.social · Aug 12

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research

psychedelicalpha.com/news/from-hu...

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research - Psychedelic Alpha

Dr. Alaina Jaster speaks with Dr. Mark Geyer in a discussion that traces his path to psychedelics research, the field’s scientific and cultural shifts, and the role of the Heffter Research Institute.

psychedelicalpha.com

4 6

josh hardman @josh-hardman.bsky.social · Aug 8

Bulletin 206:

- Q2’25 Psychedelic Lobbying Update

- Tabernanthalog Spurs Neuroplasticity via Alternative Pathway, Davis and Delix Researchers Find

- UK Moves Toward Easing Schedule I Research Restrictions But Keeps Industry at Arm’s Length

- and more:

psychedelicalpha.com/news/p%ce%b1...

Pα+ Psychedelic Bulletin #206: Q2’25 Psychedelic Lobbying; Tabernanthalog’s Neuroplasticity Pathway; UK Moves to Ease Schedule I Research Restrictions - Psychedelic Alpha

Q2’25 Psychedelic Lobbying Update • Tabernanthalog Spurs Neuroplasticity via Alternative Pathway, Davis and Delix Researchers Find • UK Moves Toward Easing Schedule I Research Restrictions But Keeps…

psychedelicalpha.com

1 1

josh hardman @josh-hardman.bsky.social · Aug 5

At-Home Ketamine “Completely Irresponsible”, Says UK Expert

“In the psychedelic world, we are very aware that context is important,” Professor Celia Morgan said, referring to set and setting, as well as the social matrix surrounding the drug user.

psychedelicalpha.com/news/therapy...

2 3

josh hardman @josh-hardman.bsky.social · Aug 5

Therapy or Threat? UK Expert Warns of Rising Ketamine Addiction as Phase III Alcoholism Trial Launches

Charles Bliss speaks with Professor Celia Morgan about ketamine's promise and pitfalls.

psychedelicalpha.com/news/therapy...

Therapy or Threat? UK Expert Warns of Rising Ketamine Addiction as Phase III Alcoholism Trial Launches - Psychedelic Alpha

Psychedelic Alpha’s Charles Bliss speaks with Professor Celia Morgan, a leading ketamine researcher, about the promise of ketamine-assisted therapy for alcohol use disorder…

psychedelicalpha.com

josh hardman @josh-hardman.bsky.social · Aug 4

Last Week in Psychedelics.

Bookmark the live Feed: psychedelicalpha.com/live

2

josh hardman @josh-hardman.bsky.social · Aug 1

Pα+ Psychedelic Bulletin #205:

- AbbVie Eyes Gilgamesh

- Psychedelics Use Increases in U.S.

- FDA Moves to Ban Kraton Compound 7-OH

- What Is Sinema Selling?

- and much, much more (5,000+ words!)

psychedelicalpha.com/news/p%ce%b1...

Pα+ Psychedelic Bulletin #205: AbbVie Eyes Gilgamesh; Psychedelics Use Increases in U.S.; FDA Moves to Ban Kraton Compound 7-OH; What Is Sinema Selling? - Psychedelic Alpha

AbbVie Eyes Billion-Dollar Gilgamesh Acquisition • What Is Kyrsten Sinema Selling? • Compass ‘Encouraged’ by Germany’s Psilocybin Compassionate Use Program • Psychedelics Industry’s Input on EMA’s Dra...

psychedelicalpha.com

2

josh hardman @josh-hardman.bsky.social · Jul 31

Germany joins Switzerland in allowing certain European patients to access psilocybin when they have exhausted other options.

The imprimatur of Swiss engineering & German efficiency and process-focus could add to psychedelic medicine’s legitimacy.

More: psychedelicalpha.com/news/germany...

2

josh hardman @josh-hardman.bsky.social · Jul 31

BREAKING: German regulators have green-lit the EU's first psilocybin compassionate access program.

Unlike other countries’ pre-approval pathways, Germany’s does not require case-by-case regulatory approval and may see insurers cover costs.

Details: psychedelicalpha.com/news/germany...

Germany Establishes EU’s First Psilocybin Compassionate Access Program - Psychedelic Alpha

Germany has become the first EU country to allow legal access to psilocybin under a compassionate use program for treatment-resistant depression. Unlike other countries’ pre-approval pathways, Germany...

psychedelicalpha.com

3 11